Clinical Report: Evaluating the Transition Between Complement Inhibitors in PNH
Overview
This study presents findings on the transition strategies between complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria (PNH). The largest cohort to date was analyzed to establish consensus on managing treatment changes and avoiding breakthrough hemolysis.
Background
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by uncontrolled complement activation leading to severe anemia and other complications. The introduction of complement inhibitors has changed PNH management, yet guidance on switching between these therapies remains limited. Understanding the implications of treatment transitions is crucial for optimizing patient outcomes.
Data Highlights
Parameter
Value
Number of Patients
65
Median Age at Diagnosis
40 years
Mean Duration on CI
105.5 months
Indications for CI
Hemolysis (78%), Hemolysis and Thrombosis (9%), Thrombosis (5%)
Key Findings
65 patients were included from nine centers, with a median age of 40 years at PNH diagnosis.
Indications for complement inhibition included hemolysis in 78% of patients.
149 changes in complement inhibitors were documented, with 75 being terminal-to-proximal transitions.
Initial treatment responses varied, with 6 patients achieving complete response and 24 good response.
Criteria for breakthrough hemolysis were defined based on lactate dehydrogenase levels.
Clinical Implications
Clinicians should be aware of the complexities involved in transitioning between complement inhibitors in PNH patients.
Conclusion
The findings from this study contribute to the understanding of treatment transitions in PNH.
by Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun-ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj
